Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Corifollitropin Alfa · ORG-36286, SCH 900962

Recombinant protein · Agonist of Follicle-stimulating hormone receptor (FSHR) · developed by Organon and Co

N/A Most advanced trial (none active)
OGN Developer
4 Registered trials

What is Corifollitropin Alfa?

Corifollitropin alfa is a long-acting recombinant follicle-stimulating hormone analogue given as a single subcutaneous injection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ORG-36286, SCH 900962, MK-8962
Drug type
Recombinant protein
Targets
Follicle-stimulating hormone receptor (FSHR)
Mechanism
Agonist of Follicle-stimulating hormone receptor (FSHR)
Pathways
follicular development, ovarian stimulation
Therapy area
Women's health
Developer
Organon and Co (OGN)
FDA status
Investigational, not approved in the US. Most advanced trial: N/A
UNII
T7K20Y2GWY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00702234 N/A Pregnancy Completed OGN
NCT00703014 N/A Pregnancy Completed OGN
NCT00702273 N/A In Vitro Fertilization Completed OGN
NCT00702520 N/A Pregnancy Completed OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

In Vitro FertilizationNeonatesPregnancy

Other drugs acting on FSHR

More from Organon and Co

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.

Follow OGN, the company behind Corifollitropin Alfa

See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.